| { | |
| "industryId": "medicalDevice", | |
| "name": "의료기기", | |
| "totalRevenue": 58351, | |
| "nodeCount": 57, | |
| "stages": [ | |
| { | |
| "key": "diagnostic", | |
| "name": "진단", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "nodes": [ | |
| { | |
| "stockCode": "099190", | |
| "corpName": "아이센스", | |
| "stage": "diagnostic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 3154, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": 0.2, | |
| "opMargin": 1.2, | |
| "debtRatio": 70.2, | |
| "revCagr": -33.8, | |
| "profGrade": "저수익", | |
| "debtGrade": "주의", | |
| "growthGrade": "급감" | |
| }, | |
| { | |
| "stockCode": "206640", | |
| "corpName": "바디텍메드", | |
| "stage": "diagnostic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 1621, | |
| "confidence": 0.867, | |
| "source": "docs", | |
| "roe": 3.0, | |
| "opMargin": 23.0, | |
| "debtRatio": 15.4, | |
| "revCagr": 12.9, | |
| "profGrade": "우수", | |
| "debtGrade": "관찰", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "036220", | |
| "corpName": "오상헬스케어", | |
| "stage": "diagnostic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 1286, | |
| "confidence": 0.933, | |
| "source": "docs", | |
| "roe": -0.1, | |
| "opMargin": 15.2, | |
| "debtRatio": 20.5, | |
| "revCagr": -39.9, | |
| "profGrade": "양호", | |
| "debtGrade": "안전", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "303360", | |
| "corpName": "프로티아", | |
| "stage": "diagnostic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 151, | |
| "confidence": 0.9, | |
| "source": "docs", | |
| "roe": null, | |
| "opMargin": null, | |
| "debtRatio": null, | |
| "revCagr": null, | |
| "profGrade": "", | |
| "debtGrade": "", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "314930", | |
| "corpName": "바이오다인", | |
| "stage": "diagnostic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 70, | |
| "confidence": 0.8, | |
| "source": "docs", | |
| "roe": 1.9, | |
| "opMargin": 9.3, | |
| "debtRatio": 2.0, | |
| "revCagr": null, | |
| "profGrade": "보통", | |
| "debtGrade": "관찰", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "317690", | |
| "corpName": "퀀타매트릭스", | |
| "stage": "diagnostic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 37, | |
| "confidence": 1.0, | |
| "source": "docs", | |
| "roe": -37.1, | |
| "opMargin": -102.6, | |
| "debtRatio": 51.1, | |
| "revCagr": 114.1, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "336040", | |
| "corpName": "타스컴", | |
| "stage": "diagnostic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 0, | |
| "confidence": 0.867, | |
| "source": "docs", | |
| "roe": null, | |
| "opMargin": null, | |
| "debtRatio": null, | |
| "revCagr": null, | |
| "profGrade": "", | |
| "debtGrade": "", | |
| "growthGrade": "" | |
| } | |
| ] | |
| }, | |
| { | |
| "key": "therapeutic", | |
| "name": "치료", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "nodes": [ | |
| { | |
| "stockCode": "261200", | |
| "corpName": "덴티스", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 1142, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": 11.7, | |
| "opMargin": 10.1, | |
| "debtRatio": 328.0, | |
| "revCagr": 5.5, | |
| "profGrade": "양호", | |
| "debtGrade": "관찰", | |
| "growthGrade": "성장" | |
| }, | |
| { | |
| "stockCode": "104540", | |
| "corpName": "코렌텍", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 1004, | |
| "confidence": 0.5, | |
| "source": "docs", | |
| "roe": 9.4, | |
| "opMargin": 1.4, | |
| "debtRatio": 102.6, | |
| "revCagr": 91.4, | |
| "profGrade": "보통", | |
| "debtGrade": "주의", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "372910", | |
| "corpName": "한컴라이프케어", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 921, | |
| "confidence": 0.3, | |
| "source": "docs", | |
| "roe": -1.8, | |
| "opMargin": -63.7, | |
| "debtRatio": 61.8, | |
| "revCagr": -11.4, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "급감" | |
| }, | |
| { | |
| "stockCode": "0011A0", | |
| "corpName": "액스비스", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 566, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": 17.8, | |
| "opMargin": 7.6, | |
| "debtRatio": 157.6, | |
| "revCagr": null, | |
| "profGrade": "양호", | |
| "debtGrade": "관찰", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "044780", | |
| "corpName": "에이치케이", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 542, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": -0.2, | |
| "opMargin": -4.4, | |
| "debtRatio": 36.6, | |
| "revCagr": -24.7, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "급감" | |
| }, | |
| { | |
| "stockCode": "115480", | |
| "corpName": "씨유메디칼", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 482, | |
| "confidence": 0.5, | |
| "source": "docs", | |
| "roe": 1.0, | |
| "opMargin": 25.9, | |
| "debtRatio": 69.6, | |
| "revCagr": -35.8, | |
| "profGrade": "우수", | |
| "debtGrade": "주의", | |
| "growthGrade": "급감" | |
| }, | |
| { | |
| "stockCode": "226400", | |
| "corpName": "오스테오닉", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 454, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": 3.2, | |
| "opMargin": 74.6, | |
| "debtRatio": 48.6, | |
| "revCagr": 44.3, | |
| "profGrade": "우수", | |
| "debtGrade": "주의", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "199550", | |
| "corpName": "레이저옵텍", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 257, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": -43.1, | |
| "opMargin": -56.4, | |
| "debtRatio": 52.0, | |
| "revCagr": -27.7, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "급감" | |
| }, | |
| { | |
| "stockCode": "452190", | |
| "corpName": "한빛레이저", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 242, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": 8.8, | |
| "opMargin": 11.5, | |
| "debtRatio": 36.2, | |
| "revCagr": -40.4, | |
| "profGrade": "양호", | |
| "debtGrade": "안전", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "066310", | |
| "corpName": "큐에스아이", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 233, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": 0.7, | |
| "opMargin": 5.0, | |
| "debtRatio": 6.4, | |
| "revCagr": 0.8, | |
| "profGrade": "보통", | |
| "debtGrade": "관찰", | |
| "growthGrade": "정체" | |
| }, | |
| { | |
| "stockCode": "388790", | |
| "corpName": "라이콤", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 177, | |
| "confidence": 0.8, | |
| "source": "docs", | |
| "roe": null, | |
| "opMargin": null, | |
| "debtRatio": null, | |
| "revCagr": null, | |
| "profGrade": "", | |
| "debtGrade": "", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "043100", | |
| "corpName": "알파AI", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 168, | |
| "confidence": 0.6, | |
| "source": "docs", | |
| "roe": -21.1, | |
| "opMargin": -5.6, | |
| "debtRatio": 127.3, | |
| "revCagr": -34.1, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "급감" | |
| }, | |
| { | |
| "stockCode": "199290", | |
| "corpName": "바이오프로테크", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 0, | |
| "confidence": 0.6, | |
| "source": "docs", | |
| "roe": null, | |
| "opMargin": null, | |
| "debtRatio": null, | |
| "revCagr": null, | |
| "profGrade": "", | |
| "debtGrade": "", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "200580", | |
| "corpName": "메디쎄이", | |
| "stage": "therapeutic", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 0, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": null, | |
| "opMargin": null, | |
| "debtRatio": null, | |
| "revCagr": null, | |
| "profGrade": "", | |
| "debtGrade": "", | |
| "growthGrade": "" | |
| } | |
| ] | |
| }, | |
| { | |
| "key": "imaging", | |
| "name": "영상", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "nodes": [ | |
| { | |
| "stockCode": "011560", | |
| "corpName": "세보엠이씨", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 7158, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": 3.6, | |
| "opMargin": 4.7, | |
| "debtRatio": 68.4, | |
| "revCagr": -4.9, | |
| "profGrade": "저수익", | |
| "debtGrade": "안전", | |
| "growthGrade": "역성장" | |
| }, | |
| { | |
| "stockCode": "092790", | |
| "corpName": "넥스틸", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 5510, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": 7.7, | |
| "opMargin": 32.8, | |
| "debtRatio": 48.4, | |
| "revCagr": -55.6, | |
| "profGrade": "우수", | |
| "debtGrade": "안전", | |
| "growthGrade": "급감" | |
| }, | |
| { | |
| "stockCode": "215360", | |
| "corpName": "우리산업", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 5320, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": 4.3, | |
| "opMargin": 2.2, | |
| "debtRatio": 201.6, | |
| "revCagr": 16.1, | |
| "profGrade": "저수익", | |
| "debtGrade": "주의", | |
| "growthGrade": "성장" | |
| }, | |
| { | |
| "stockCode": "043150", | |
| "corpName": "바텍", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 4264, | |
| "confidence": 1.0, | |
| "source": "product", | |
| "roe": 81.5, | |
| "opMargin": 16.7, | |
| "debtRatio": 38.5, | |
| "revCagr": -1.7, | |
| "profGrade": "우수", | |
| "debtGrade": "안전", | |
| "growthGrade": "역성장" | |
| }, | |
| { | |
| "stockCode": "036030", | |
| "corpName": "케이티알파", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 3959, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": 0.6, | |
| "opMargin": 2.0, | |
| "debtRatio": 76.8, | |
| "revCagr": null, | |
| "profGrade": "저수익", | |
| "debtGrade": "안전", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "125020", | |
| "corpName": "티씨머티리얼즈", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 2991, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": null, | |
| "opMargin": null, | |
| "debtRatio": null, | |
| "revCagr": null, | |
| "profGrade": "", | |
| "debtGrade": "", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "100120", | |
| "corpName": "뷰웍스", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 2393, | |
| "confidence": 1.0, | |
| "source": "product", | |
| "roe": 0.9, | |
| "opMargin": 8.0, | |
| "debtRatio": 46.8, | |
| "revCagr": -0.2, | |
| "profGrade": "보통", | |
| "debtGrade": "안전", | |
| "growthGrade": "역성장" | |
| }, | |
| { | |
| "stockCode": "041830", | |
| "corpName": "인바디", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 2339, | |
| "confidence": 1.0, | |
| "source": "docs", | |
| "roe": 3.5, | |
| "opMargin": 65.4, | |
| "debtRatio": 12.9, | |
| "revCagr": -29.5, | |
| "profGrade": "우수", | |
| "debtGrade": "안전", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "336570", | |
| "corpName": "원텍", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 1568, | |
| "confidence": 0.8, | |
| "source": "docs", | |
| "roe": 6.4, | |
| "opMargin": 27.8, | |
| "debtRatio": 61.7, | |
| "revCagr": 12.1, | |
| "profGrade": "우수", | |
| "debtGrade": "안전", | |
| "growthGrade": "성장" | |
| }, | |
| { | |
| "stockCode": "214680", | |
| "corpName": "디알텍", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 1163, | |
| "confidence": 1.0, | |
| "source": "product", | |
| "roe": -35.2, | |
| "opMargin": -40.8, | |
| "debtRatio": 171.8, | |
| "revCagr": 23.4, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "228850", | |
| "corpName": "레이언스", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 1147, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": -2.2, | |
| "opMargin": -13.6, | |
| "debtRatio": 11.3, | |
| "revCagr": -8.3, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "역성장" | |
| }, | |
| { | |
| "stockCode": "240550", | |
| "corpName": "동방메디컬", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 1135, | |
| "confidence": 0.5, | |
| "source": "docs", | |
| "roe": 10.0, | |
| "opMargin": 3.6, | |
| "debtRatio": 51.9, | |
| "revCagr": null, | |
| "profGrade": "양호", | |
| "debtGrade": "안전", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "122310", | |
| "corpName": "제노레이", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 1080, | |
| "confidence": 0.8, | |
| "source": "docs", | |
| "roe": -2.2, | |
| "opMargin": -1.1, | |
| "debtRatio": 57.8, | |
| "revCagr": 5.3, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "정체" | |
| }, | |
| { | |
| "stockCode": "263690", | |
| "corpName": "디알젬", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 1027, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": 1.3, | |
| "opMargin": 7.8, | |
| "debtRatio": 39.7, | |
| "revCagr": -40.4, | |
| "profGrade": "보통", | |
| "debtGrade": "주의", | |
| "growthGrade": "급감" | |
| }, | |
| { | |
| "stockCode": "179290", | |
| "corpName": "엠아이텍", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 672, | |
| "confidence": 0.8, | |
| "source": "docs", | |
| "roe": null, | |
| "opMargin": 30.8, | |
| "debtRatio": 12.6, | |
| "revCagr": null, | |
| "profGrade": "우수", | |
| "debtGrade": "안전", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "041920", | |
| "corpName": "메디아나", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 649, | |
| "confidence": 1.0, | |
| "source": "docs", | |
| "roe": 1.2, | |
| "opMargin": 8.0, | |
| "debtRatio": 11.1, | |
| "revCagr": -38.8, | |
| "profGrade": "보통", | |
| "debtGrade": "안전", | |
| "growthGrade": "급감" | |
| }, | |
| { | |
| "stockCode": "081180", | |
| "corpName": "쎄크", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 592, | |
| "confidence": 1.0, | |
| "source": "docs", | |
| "roe": -6.9, | |
| "opMargin": -12.2, | |
| "debtRatio": 178.2, | |
| "revCagr": null, | |
| "profGrade": "적자", | |
| "debtGrade": "고위험", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "206560", | |
| "corpName": "덱스터", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 554, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": -16.0, | |
| "opMargin": -7.7, | |
| "debtRatio": 150.6, | |
| "revCagr": 58.7, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "037950", | |
| "corpName": "엘컴텍", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 463, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": -0.0, | |
| "opMargin": 4.8, | |
| "debtRatio": 17.1, | |
| "revCagr": 3.6, | |
| "profGrade": "저수익", | |
| "debtGrade": "안전", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "156100", | |
| "corpName": "엘앤케이바이오", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 389, | |
| "confidence": 0.8, | |
| "source": "docs", | |
| "roe": -1.7, | |
| "opMargin": 15.2, | |
| "debtRatio": 112.6, | |
| "revCagr": 23.3, | |
| "profGrade": "양호", | |
| "debtGrade": "주의", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "398120", | |
| "corpName": "에스지헬스케어", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 246, | |
| "confidence": 1.0, | |
| "source": "docs", | |
| "roe": -1.8, | |
| "opMargin": -8.7, | |
| "debtRatio": 66.3, | |
| "revCagr": null, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "302550", | |
| "corpName": "리메드", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 245, | |
| "confidence": 0.8, | |
| "source": "docs", | |
| "roe": 0.4, | |
| "opMargin": 4.2, | |
| "debtRatio": 40.3, | |
| "revCagr": 8.4, | |
| "profGrade": "저수익", | |
| "debtGrade": "관찰", | |
| "growthGrade": "정체" | |
| }, | |
| { | |
| "stockCode": "296640", | |
| "corpName": "이노룰스", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 229, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": 1.6, | |
| "opMargin": 15.4, | |
| "debtRatio": 39.3, | |
| "revCagr": 14.7, | |
| "profGrade": "양호", | |
| "debtGrade": "안전", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "258830", | |
| "corpName": "세종메디칼", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 185, | |
| "confidence": 1.0, | |
| "source": "docs", | |
| "roe": 4.9, | |
| "opMargin": 12.2, | |
| "debtRatio": 147.6, | |
| "revCagr": 65.8, | |
| "profGrade": "양호", | |
| "debtGrade": "안전", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "043090", | |
| "corpName": "더테크놀로지", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 126, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": -93.4, | |
| "opMargin": -158.7, | |
| "debtRatio": 32.8, | |
| "revCagr": 55.2, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "고성장" | |
| }, | |
| { | |
| "stockCode": "411080", | |
| "corpName": "샌즈랩", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 116, | |
| "confidence": 0.7, | |
| "source": "product", | |
| "roe": -0.9, | |
| "opMargin": -203.3, | |
| "debtRatio": 8.0, | |
| "revCagr": null, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "058110", | |
| "corpName": "멕아이씨에스", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 113, | |
| "confidence": 0.867, | |
| "source": "docs", | |
| "roe": 1.8, | |
| "opMargin": 9.4, | |
| "debtRatio": 54.0, | |
| "revCagr": 2.4, | |
| "profGrade": "보통", | |
| "debtGrade": "관찰", | |
| "growthGrade": "정체" | |
| }, | |
| { | |
| "stockCode": "405000", | |
| "corpName": "플라즈맵", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 85, | |
| "confidence": 0.8, | |
| "source": "docs", | |
| "roe": -12.1, | |
| "opMargin": -208.4, | |
| "debtRatio": 186.5, | |
| "revCagr": -57.2, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "급감" | |
| }, | |
| { | |
| "stockCode": "0088M0", | |
| "corpName": "메쥬", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 74, | |
| "confidence": 1.0, | |
| "source": "docs", | |
| "roe": null, | |
| "opMargin": null, | |
| "debtRatio": null, | |
| "revCagr": null, | |
| "profGrade": "", | |
| "debtGrade": "", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "412350", | |
| "corpName": "레이저쎌", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 47, | |
| "confidence": 0.8, | |
| "source": "docs", | |
| "roe": -15.9, | |
| "opMargin": -247.1, | |
| "debtRatio": 94.9, | |
| "revCagr": -45.4, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "급감" | |
| }, | |
| { | |
| "stockCode": "212310", | |
| "corpName": "오건에코텍", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 0, | |
| "confidence": 0.8, | |
| "source": "docs", | |
| "roe": null, | |
| "opMargin": null, | |
| "debtRatio": null, | |
| "revCagr": null, | |
| "profGrade": "", | |
| "debtGrade": "", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "244880", | |
| "corpName": "나눔테크", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 0, | |
| "confidence": 1.0, | |
| "source": "docs", | |
| "roe": null, | |
| "opMargin": null, | |
| "debtRatio": null, | |
| "revCagr": null, | |
| "profGrade": "", | |
| "debtGrade": "", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "332190", | |
| "corpName": "오션스바이오", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 0, | |
| "confidence": 1.0, | |
| "source": "docs", | |
| "roe": null, | |
| "opMargin": null, | |
| "debtRatio": null, | |
| "revCagr": null, | |
| "profGrade": "", | |
| "debtGrade": "", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "337840", | |
| "corpName": "유엑스엔", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 0, | |
| "confidence": 0.8, | |
| "source": "docs", | |
| "roe": null, | |
| "opMargin": null, | |
| "debtRatio": null, | |
| "revCagr": null, | |
| "profGrade": "", | |
| "debtGrade": "", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "390110", | |
| "corpName": "애니메디솔루션", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 0, | |
| "confidence": 0.7, | |
| "source": "docs", | |
| "roe": null, | |
| "opMargin": null, | |
| "debtRatio": null, | |
| "revCagr": null, | |
| "profGrade": "", | |
| "debtGrade": "", | |
| "growthGrade": "" | |
| }, | |
| { | |
| "stockCode": "491000", | |
| "corpName": "리브스메드", | |
| "stage": "imaging", | |
| "role": "제조", | |
| "stream": "midstream", | |
| "revenue": 0, | |
| "confidence": 0.5, | |
| "source": "docs", | |
| "roe": -12.6, | |
| "opMargin": -44.2, | |
| "debtRatio": 11.6, | |
| "revCagr": null, | |
| "profGrade": "적자", | |
| "debtGrade": "주의", | |
| "growthGrade": "" | |
| } | |
| ] | |
| } | |
| ], | |
| "unclassified": [], | |
| "edges": [ | |
| { | |
| "from": "228850", | |
| "to": "043150", | |
| "type": "supplier", | |
| "amount": null, | |
| "ratio": null, | |
| "product": "", | |
| "confidence": 0.9, | |
| "source": "docs_table" | |
| }, | |
| { | |
| "from": "036220", | |
| "to": "336040", | |
| "type": "affiliate", | |
| "amount": null, | |
| "ratio": null, | |
| "product": "", | |
| "confidence": 0.5, | |
| "source": "docs" | |
| }, | |
| { | |
| "from": "043150", | |
| "to": "228850", | |
| "type": "affiliate", | |
| "amount": null, | |
| "ratio": null, | |
| "product": "", | |
| "confidence": 0.5, | |
| "source": "docs" | |
| }, | |
| { | |
| "from": "044780", | |
| "to": "200580", | |
| "type": "supplier", | |
| "amount": null, | |
| "ratio": null, | |
| "product": "", | |
| "confidence": 0.7, | |
| "source": "docs" | |
| }, | |
| { | |
| "from": "228850", | |
| "to": "043150", | |
| "type": "affiliate", | |
| "amount": null, | |
| "ratio": null, | |
| "product": "", | |
| "confidence": 0.5, | |
| "source": "docs" | |
| }, | |
| { | |
| "from": "036220", | |
| "to": "336040", | |
| "type": "investor", | |
| "amount": null, | |
| "ratio": null, | |
| "product": "", | |
| "confidence": 0.6, | |
| "source": "network" | |
| } | |
| ] | |
| } |